Pure Body Flow
MedCity News Healthcare technology news, life science current events
- Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMsby Marissa Plescia on October 30, 2026 at 7:40 pm
The Department of Labor finalized a rule that seeks to bring more transparency into PBM compensation. The post Employer, Pharmacy Advocates Applaud DOL Final Rule on PBMs appeared first on MedCity News.
- Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’by Frank Vinluan on October 30, 2026 at 5:13 pm
Bambusa Therapeutics’ IPO cash will support its pipeline of bispecific antibodies designed to offer advantages over currently available monoclonal antibodies. Aspen Neuroscience also debuted on the Nasdaq as it prepares for a pivotal test of its Parkinson’s disease cell therapy. The post Bambusa IPO Brings In $169M to Break Immunology’s ‘Therapeutic Ceiling’ appeared first on MedCity News.
- It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreementsby Paul R. Piccigallo on October 30, 2026 at 1:56 pm
For life science employers who offer these benefits should pay particular attention to new state laws and regulations to ensure continued compliance. The post It’s A TRAP! Employer Concerns for Tuition Reimbursement and Other Employee Repayment Agreements appeared first on MedCity News.
- A Meaningful Signal on Palliative Care – But Not Yet a Benefitby Jill Schwartz-Chevlin on October 30, 2026 at 1:53 pm
CMS asked the right questions – the ones that will determine whether any future benefit actually reaches these patients. The post A Meaningful Signal on Palliative Care – But Not Yet a Benefit appeared first on MedCity News.
- What’s Driving the Rise of Consumer Diagnostics?by Marissa Plescia on October 29, 2026 at 10:06 pm
At MedCity INVEST Digital Health, experts from Jona, Labcorp and Evvy discussed the drivers of consumer diagnostics. The post What’s Driving the Rise of Consumer Diagnostics? appeared first on MedCity News.
- BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drugby Frank Vinluan on October 29, 2026 at 7:39 pm
BioMarin gains rights to a Fabry disease enzyme replacement therapy with potential dosing advantages over products from Sanofi and Chiesi Group. BioMarin’s new clinical-stage asset could reach patients ineligible for the Fabry drug that came with its Amicus Therapeutics acquisition earlier this year. The post BioMarin Expands Again in Enzyme Replacement, Paying $70M for Long-Acting Fabry Drug appeared first on MedCity News.
- Beyond a Score: Putting The Patient Experience at the Heart of OCD Innovationby Hannah Ellis and Nick Sireau on October 29, 2026 at 1:36 pm
Scientific progress only really matters if it changes what life looks like for those living with OCD. That’s because for someone who has spent years losing hours to their obsessions and compulsions, meaningful progress should mean a significant change in their lives. The post Beyond a Score: Putting The Patient Experience at the Heart of OCD Innovation appeared first on MedCity News.
- 3 Ways ProgenyHealth Can Transform Maternity and Infant Health, Claims Managementby Stephanie Baum on October 29, 2026 at 11:30 am
[Sponsored] Pregnancy and NICU admissions are among the most complex areas in healthcare. A new report from ProgenyHealth highlights how the company can work with Medicaid and commercial health plans to uncover insights and hidden risks critical to improving maternal and infant care and reducing costs. The post 3 Ways ProgenyHealth Can Transform Maternity and Infant Health, Claims Management appeared first on MedCity News.
- Senators Investigate Insurers’ Role in Removing Thousands from ACA Coverageby Marissa Plescia on October 28, 2026 at 11:26 pm
Democratic senators are investigating 10 insurers’ role in the Trump administration’s termination of 760,000 ACA enrollees’ coverage over suspected fraud. The post Senators Investigate Insurers’ Role in Removing Thousands from ACA Coverage appeared first on MedCity News.
- Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trialby Frank Vinluan on October 28, 2026 at 6:06 pm
Topline Phase 3 results show Eli Lilly’s retatrutide beat Novo’s Ozempic on measures of blood sugar and weight loss in adults with type 2 diabetes. Retatrutide is a peptide designed to activate three metabolic targets versus just one hit by Ozempic. The post Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial appeared first on MedCity News.
- Ahead of Midterms, HFMA Calls for Cross-Sector Action on Healthcare Affordabilityby Jenna Congdon on October 28, 2026 at 3:53 pm
With healthcare affordability set to influence voters’ decisions in next week’s midterm elections, the Healthcare Financial Management Association is calling on healthcare leaders to move beyond finger-pointing and work together to address rising costs. HFMA is urging financial leaders across healthcare to sign its Declaration on Healthcare Affordability and Sustainability. The post Ahead of Midterms, HFMA Calls for Cross-Sector Action on Healthcare Affordability appeared first on MedCity News.
- Work Requirements Put New Pressure On Medicaid Member Retentionby John Marchisin on October 28, 2026 at 1:53 pm
By using existing data to better understand members and implementing retention strategies, plans can remain sustainable and members can get the care they need. The post Work Requirements Put New Pressure On Medicaid Member Retention appeared first on MedCity News.
- How Can Hospitals and Pharmacists Collaborate on Effective Stewardship Programs for Opioids and Antibiotics?by Stephanie Baum on October 28, 2026 at 1:42 pm
[Sponsored] A webinar sponsored by Inovalon explored how hospitals and pharmacies can work together to generate the best outcomes for patients while improving patient safety. The post How Can Hospitals and Pharmacists Collaborate on Effective Stewardship Programs for Opioids and Antibiotics? appeared first on MedCity News.
- Willow Acquires 2 Women’s Health Companiesby Marissa Plescia on October 27, 2026 at 10:01 pm
Willow Innovations acquired Swehl and Momtech to expand its maternal health offerings beyond breast pumps. The post Willow Acquires 2 Women’s Health Companies appeared first on MedCity News.
- Patient Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artivaby Frank Vinluan on October 27, 2026 at 9:07 pm
Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the cell therapy itself. But Artiva’s setbacks follow safety signals reported for autoimmune disease cell therapy programs from Novartis and Bristol Myers Squibb. The post Patient Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva appeared first on MedCity News.















